

10.1.3.2. 510(k) Summary of Safety and Effectiveness
Information Capnostream₂₀ and Capnostream

**510(k) Summary of Safety and Effectiveness Information
Capnostream₂₀ and Capnostream₁₀**

(This document is not confidential)

DATE THIS SUMMARY WAS PREPARED

March 20, 2006

SUBMITTERS NAME AND ESTABLISHMENT ADDRESS:

Oridion Capnography Inc.
21 Highland Circle
Needham, MA 02494-3038

PRODUCT NAMES

NOTE: This summary statement is for a bundled submission and covers the Capnostream₂₀
and Capnostream₁₀

Capnostream₂₀

Proprietary: Capnostream₂₀
Common: Two Parameter Bedside Monitor

Capnostream₁₀

Proprietary: Capnostream₁₀
Common: One Parameter Bedside Monitor

ESTABLISHMENT REGISTRATION NUMBER

Establishment Registration Number: 3003941644

CONTACT PERSON:

Sanford Brown, Regulatory Affairs Director
Oridion Medical 1987 Ltd.
Har Hotzvim Science Based Industrial Park
POB 45025
91450 Jerusalem, Israel
Telephone: +972-2-589-9115
FAX: +972-2-586-6680

B051971

DEVICE DESCRIPTIONS

❖ Capnostream₂₀

The Capnostream₂₀ bedside monitor is a two parameter monitor consisting of an EtCO₂ MiniMediCO₂ module and a MP100 SpO₂ module, displays and alarms.

SUBSTANTIAL EQUIVALENCE INFORMATION

- **CO₂ Module (MiniMediCO₂)** used in legally marketed Predicate Devices:
 - ✓ Oridion Polaris 2004, K040011,
 - ✓ CAS Medical Systems, Inc Models 750c-2ms, 750cm-2ms, 750c-Nnl, 750cm with MiniMediCO₂-V1 K050844
 - ✓ Larsen & Toubro Limited Star 50 Monitoring System K051608
- **Pulse Oximeter Module, SpO₂ Module (MP100)** used in legally marketed Predicate Devices:
 - ✓ NPB OxiMax Pulse Oximeter System With N-595 Pulse Oximeter, K012891
 - ✓ NPB Oximax N-550, K021090
- **Nurse Call**
 - ✓ NPB OxiMax Pulse Oximeter System With N-595 Pulse Oximeter, K012891
 - ✓ Welch Allyn Atlas Monitor K022084

CLASSIFICATION

Capnostream₂₀

73CCK Class II

This device has two modules that are classified as follows:

- 21 CFR 868.1400, carbon dioxide analyzer
- 21 CFR870.2700 Pulse Oximeter

INTENDED USE

The Capnostream₂₀ is intended for CO₂ and SpO₂ indications. The Capnostream₂₀ combined capnograph/pulse oximeter monitor is intended to provide professionally trained health care providers the continuous, non invasive measurement and monitoring of carbon dioxide concentration of the expired and inspired breath and respiration rate, and for the continuous non-invasive monitoring of functional oxygen saturation of arterial hemoglobin (SpO₂ and pulse rate). It is intended for use with neonatal, pediatric and adult patients in hospitals, hospital type facilities, intra hospital moves and home environments.

DEVICE DESCRIPTION

The Capnostream₂₀ Bedside Monitor is comprised of two modules used in previously FDA cleared devices with the following indications for use, which together are the indications for use for the two parameter bedside monitor:

Capnostream₂₀**1. The MiniMediCO₂ EtCO₂ Module:**

Is intended for installation in host devices that: are used by physicians, nurses and other trained health care providers in critical care patient settings, such as anesthesiology, intensive care medicine, neonatal Intensive care and other health care areas where non invasive measurement of expired CO₂ and inspired CO₂ are of medical value. It continuously and non invasively measures and monitors carbon dioxide concentration of the expired and inspired breath and respiration rate. This module is designed to be installed in a host device, in this case the two Parameter Bedside Monitor, that is for prescription use only.

2. The MP100 Oximetry Module

Is indicated for the continuous non-invasive monitoring of functional oxygen saturation of arterial hemoglobin (SpO₂) and pulse rate. It is intended for use with neonatal, pediatric, and adult patients during both no motion and motion conditions and for patients who are either well or poorly perfused. It is to be used by physicians, nurses and other trained health care providers in critical care patient settings, such as anesthesiology, intensive care medicine, neonatal Intensive care and other health care areas. This module is designed to be installed in a host device, in this case the two Parameter Bedside Monitor, that is for prescription use only.

❖ Capnostream₁₀**Capnostream₁₀**

Proprietary: Capnostream₁₀

Common: One Parameter Bedside Monitor

ESTABLISHMENT REGISTRATION NUMBER

Establishment Registration Number: 3003941644

CONTACT PERSON:

Sanford Brown, Regulatory Affairs Director

Oridion Medical 1987 Ltd.

Har Hotzvim Science Based Industrial Park

POB 45025

91450 Jerusalem, Israel

DEVICE LISTING FDA FORM 2892:

B051971

DEVICE DESCRIPTION

The Capnostream₁₀ bedside monitor is a one parameter monitor consisting of a MP100 EtCO₂ module displays and alarms.

SUBSTANTIAL EQUIVALENCE INFORMATION

- **CO₂ Module (MiniMediCO₂) used in Predicate Devices:**
 - ✓ Oridion Polaris 2004, K040011,
 - ✓ CAS Medical Systems, Inc Models 750c-2ms, 750cm-2ms, 750c-Nnl, 750cm with MiniMediCO₂-V1 K050844
 - ✓ Larsen & Toubro Limited Star 50 Monitoring System K051608

CLASSIFICATION

Capnostream₁₀

73CCK Class II

This device is classified as follows:

- 21 CFR 868.1400, carbon dioxide analyzer

INTENDED USE

The Capnostream₁₀ is intended for CO₂ indications only. The Capnostream₁₀ is intended to provide professionally trained health care providers the continuous, non invasive measurement and monitoring of carbon dioxide concentration of the expired and inspired breath. It is intended for use with neonatal, pediatric and adult patients in hospitals, hospital type facilities, intra hospital moves and home environments.

DEVICE DESCRIPTION

The Capnostream₁₀ Bedside Monitor contains a MiniMediCO₂ EtCO₂ module used in previously FDA cleared devices with the following indications for use.

The MiniMediCO₂ EtCO₂ Module:

Is intended for installation in host devices that: are used by physicians, nurses and other trained health care providers in critical care patient settings, such as anesthesiology, intensive care medicine, neonatal Intensive care and other health care areas where non invasive measurement of expired CO₂ and inspired CO₂ are of medical value. It continuously and non invasively measure and monitor carbon dioxide concentration of the expired and inspired breath and respiration rate.

This module is designed to be installed in a host device, in this case the one Parameter Bedside Monitor, that is for prescription use only.



MAY - 4 2006

Food and Drug Administration
9200 Corporate Boulevard
Rockville MD 20850

Oridion Capnography, Incorporated
C/O Mr. Stanford Brown
Regulatory Affairs Director
Oridion Medical 1987 Limited
Har Hotzvim Science Based Industrial Park
POB 45025
91450 Jerusalem, Israel

Re: K060065
Trade/Device Name: Capnostream₂₀
Regulation Number: 870.2700
Regulation Name: Oximeter
Regulatory Class: II
Product Code: DQA
Dated: April 6, 2006
Received: April 7, 2006

Dear Mr. Brown:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0120. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address <http://www.fda.gov/cdrh/industry/support/index.html>.

Sincerely yours,



Chiu Lin, Ph.D.

Director

Division of Anesthesiology, General Hospital,

Infection Control and Dental Devices

Office of Device Evaluation

Center for Devices and

Radiological Health

Enclosure

